Growing Revenue Streams Amarin's recent Q1 2026 revenue of 45.1 million dollars, driven by consistent US sales and a significant increase in licensing and royalty income, indicates strong market demand and licensing opportunities for cardiovascular products globally.

International Expansion The company's successful launch of VAZKEPA in three additional European markets demonstrates ongoing international growth potential, offering new sales opportunities through regional reimbursement and market entry strategies.

Strategic Partnerships Amarin’s distribution model relies heavily on partnering with well-established international distributors, which provides access to over 90 markets, creating numerous opportunities to expand product reach and develop new commercial collaborations.

R&D and Clinical Focus Continued presentation of in vitro mechanistic data at major scientific events underscores Amarin’s focus on research-driven growth, positioning the company as a key player in innovative cardiovascular treatments that can attract research and development partnership opportunities.

Leadership and Growth Recent leadership appointments, including the hiring of a new CFO and board member, suggest a strategic focus on strengthening corporate governance and financial management, which can support scaling sales efforts and exploring new market segments.